Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04458311 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT04458311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1/2
Overall status
Terminated
Start date
December 1, 2020
Completion date
November 15, 2023
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer